...
首页> 外文期刊>The Professional Medical Journal >INTRA TYMPANIC INJECTION OF LOW DOSE GENTAMICIN IN THE TREATMENT
【24h】

INTRA TYMPANIC INJECTION OF LOW DOSE GENTAMICIN IN THE TREATMENT

机译:低剂量庆大霉素的鼓室内注射治疗

获取原文
           

摘要

Meniere's disease is chronic progressive disease with unclear idiopathic etiology and symptomatic improvements with treatment. Objectives: To analyze the efficacy of low dose intratympanic injection of gentamicin for vertigo control in unilateral Meniere's disease. Study Design: Quasi experimental study. Settings: Department of ENT, PIMS, NESCOM & IMDC Islamabad. Materials & Methods: Gentamicin was used intra tympanically in this multicentre study of 75 patients over a period of 8.5 years between 1 st January 2005 to 30 th June 2013 in definite Meniere's disease according to the 1995 Document of American academy of otolaryngology- Head and Neck Surgery (AAO-HNS).All these centers followed same criteria and procedures. Single dose of 1 ml Gentamicin solution 40 mg/ml was instilled in the middle ear through the grommet under microscope and followed up for 3 months and two years. The staging of disease (hearing thresholds) the degree of disability (frequency of attacks per month) and the functional level were assessed before and after treatment. Results: Among 75 patients, 41 were female & 34 were males between age ranges of 25 to 70 years. Most of the patients in the study had stage 2 (23/75) and stage 3 (41/75) Meniere's disease. About 68(91%) patients were having good control of vertigo at the end of two year of intratympanic gentamicin without any loss of hearing. Conclusion: A single Low dose intratympanic gentamicin is effective in controlling vertigo in patients with Meniere's disease with no further deterioration in hearing for at least two years follow up.
机译:美尼尔氏病是一种慢性进行性疾病,其特发性病因不明确,治疗后症状有所改善。目的:分析低剂量鼓膜内注射庆大霉素在单侧美尼尔氏病中控制眩晕的疗效。研究设计:准实验研究。设置:耳鼻喉科,PIMS,NESCOM和IMDC伊斯兰堡。材料与方法:根据美国耳鼻咽喉科学会1995年文件《头颈》,在2005年1月1日至2013年6月30日之间的8.5年中,对庆大霉素治疗的75例患者进行了鼓室注射庆大霉素。手术(AAO-HNS)。所有这些中心均遵循相同的标准和程序。在显微镜下通过索环将单剂量的1 ml庆大霉素溶液40 mg / ml滴入中耳,并随访3个月零2年。在治疗前后评估疾病的分期(听力阈值),残疾程度(每月发作频率)和功能水平。结果:在75例患者中,年龄在25至70岁之间的是女性41例,男性34例。该研究中的大多数患者患有2期(23/75)和3期(41/75)美尼尔氏病。大约68(91%)的患者在鼓膜内使用庆大霉素治疗两年后对眩晕的控制良好,而没有听力损失。结论:单一的低剂量鼓膜内庆大霉素可有效控制梅尼埃病患者的眩晕,并且至少在两年的随访中听力没有进一步恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号